Dermatitis Clinical Trial
— KIROfficial title:
Analysis of Killer Immunoglobulin-like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T-cell Lymphomas (Mycosis Fungoid and Sézary Syndrome) in Patients With Erythroderma or Erythematous Patches/Plaques.
Verified date | August 2012 |
Source | Assistance Publique - Hôpitaux de Paris |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
The most frequent cutaneous T-cell lymphomas (CTCL) are mycosis fungoid and Sezary syndrome. The diagnosis of these lymphomas is difficult using current methods, especially because numerous benign dermatological conditions can mimick CTCL both clinically and under microscopic examination. Recently, the KIR receptor CD158k has been shown to be a marker for Sezary syndrome in both the blood and skin. We hypothesize that other receptors from the same family may help fro the diagnosis of these lymphomas. To address this issue, we will study the expression of all known KIR receptor in the skin of patients presenting with a skin eruption, which may correspond to either a cutaneous T-cell lymphoma or a benign dermatological disease. The final diagnosis will be established by a panel of experts, allowing constitution of 2 groups of patients : the cutaneous T-cell lymphoma group, and the benign inflammatory disease group. The expression of the different KIRs will be analyzed in both group in a blinded fashion, in order to determine whether one or a several KIRs may be differentially expressed.
Status | Completed |
Enrollment | 495 |
Est. completion date | December 2011 |
Est. primary completion date | November 2011 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 95 Years |
Eligibility |
Inclusion Criteria: - Signed consent - Subacute/chronic dermatitis (>7 days) with clinical suspicion for cutaneous T-cell lymphoma - No past history of lymphoma or other hematologic malignancy - Skin biopsy for routine histology at inclusion - Cutaneous T-cell clonality analysis at inclusion - Sezary cell count on routine blood smear examination in case of erythroderma - Blood T-cell clonality analysis at inclusion in case of erythroderma - Age<18 years - Skin biopsy for routine histology at inclusion (Possibility, in the 6 previous months of inclusion without any specific treatment other taht local corticoids- amendment n°4) - Cutaneous T-cell clonality analysis at inclusion (Possibility, in the 6 previous months of inclusion without any specific treatment other taht local corticoids- amendment n°4) - Realization of a preliminary medical examination - Sezary cell count on routine blood smear examination in case of erythroderma (Possibility, in the 6 previous months of inclusion without any specific treatment other taht local corticoids- amendment n°4) - Blood T-cell clonality analysis at inclusion in case of erythroderma (Possibility, in the 6 previous months of inclusion without any specific treatment other taht local corticoids- amendment n°4) Exclusion Criteria: - Adults under tutelage - Subject not affiliated at the French National health and pensions organization |
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | Groupe hospitalier Henri Mondor - Albert Chenevier | Creteil |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Differential expression of one or a panel of KIRs transcript(s) between epidermotropic cutaneous lymphoma and inflammatory diseases | at the inclusion | Yes | |
Secondary | Difference(s) in the quantitative expression of one or a panel of KIRs transcript(s) between epidermotropic cutaneous lymphoma and inflammatory diseases | at the inclusion | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03563066 -
Effect of Benralizumab in Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT02916888 -
A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists
|
N/A | |
Recruiting |
NCT01631617 -
Effects of Treatments on Atopic Dermatitis
|
Phase 2 | |
Completed |
NCT03720470 -
Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy
|
Phase 3 | |
Recruiting |
NCT01012453 -
A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema
|
N/A | |
Completed |
NCT00375713 -
Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema
|
Phase 3 | |
Completed |
NCT00001150 -
Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
|
N/A | |
Completed |
NCT05247333 -
Implementation of a Minor Ailment Service in Community Pharmacy Practice
|
N/A | |
Withdrawn |
NCT04154033 -
Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone
|
Phase 2 | |
Completed |
NCT02979210 -
Infant Fecal Insult Study
|
N/A | |
Completed |
NCT02615912 -
A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants
|
N/A | |
Withdrawn |
NCT01125761 -
Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis
|
Phase 3 | |
Withdrawn |
NCT00746382 -
A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)
|
Phase 2 | |
Terminated |
NCT00176956 -
Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients
|
Phase 3 | |
Completed |
NCT05001139 -
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
|
N/A | |
Completed |
NCT00801502 -
Salmon in Pregnancy Study
|
N/A | |
Completed |
NCT00005781 -
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
|
N/A | |
Completed |
NCT05324618 -
Tacrolimus Versus Hydrocortisone in Atopic Dermatitis
|
Phase 4 | |
Completed |
NCT04826471 -
Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam
|
N/A | |
Recruiting |
NCT06436183 -
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
|
Phase 2 |